Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Vitamin D [EPC]
Sodium Molybdate is a trace element supplement used primarily in parenteral nutrition to prevent molybdenum deficiency. It belongs to the pharmacological classes including Vitamin D [EPC] and Standardized Chemical Allergen [EPC], serving as a vital cofactor for essential metabolic enzymes.
Name
Sodium Molybdate
Raw Name
SODIUM MOLYBDATE
Category
Vitamin D [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Sodium Molybdate
Sodium Molybdate is a trace element supplement used primarily in parenteral nutrition to prevent molybdenum deficiency. It belongs to the pharmacological classes including Vitamin D [EPC] and Standardized Chemical Allergen [EPC], serving as a vital cofactor for essential metabolic enzymes.
Detailed information about Sodium Molybdate
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Sodium Molybdate.
Sodium Molybdate (chemical formula $Na_2MoO_4$) is a soluble salt of molybdenum, a trace element that is essential for human health. While often categorized under broad nutritional headers such as Vitamin D [EPC] or Standardized Chemical Allergen [EPC] in certain regulatory databases, its primary clinical utility is as a source of molybdenum in Total Parenteral Nutrition (TPN) for patients who cannot absorb nutrients through the gastrointestinal tract. Molybdenum is a critical component of several metalloenzymes that are necessary for the metabolism of sulfur-containing amino acids and the breakdown of purines into uric acid.
In a clinical setting, Sodium Molybdate is typically administered intravenously as part of a multi-trace element solution. The FDA has recognized the necessity of molybdenum in long-term parenteral therapy since the early 1980s, following reports of severe metabolic disturbances in patients receiving molybdenum-free intravenous nutrition. Beyond its nutritional role, Sodium Molybdate is also utilized in diagnostic medicine as a standardized chemical allergen for patch testing, helping clinicians identify hypersensitivity reactions in patients exposed to industrial chemicals or medical devices, including certain copper-containing intrauterine devices.
Sodium Molybdate functions by providing the molybdenum atom required for the synthesis of the molybdenum cofactor (MoCo). This cofactor is a complex molecule that binds to specific apoenzymes to create functional holoenzymes. At the molecular level, molybdenum acts as a redox center, facilitating the transfer of oxygen atoms in various biochemical reactions.
The three primary enzymes that depend on Sodium Molybdate are:
The pharmacokinetics of Sodium Molybdate vary significantly depending on the route of administration, though it is most commonly discussed in the context of intravenous infusion.
Sodium Molybdate is indicated for the following clinical scenarios:
Sodium Molybdate is available in several formats, primarily for institutional use:
> Important: Only your healthcare provider can determine if Sodium Molybdate is right for your specific condition. The use of trace elements must be carefully monitored to prevent both deficiency and toxicity.
The dosage of Sodium Molybdate is typically calculated based on the elemental molybdenum content. For adults receiving Total Parenteral Nutrition (TPN), the standard recommended daily intake is:
When used as a chemical allergen for patch testing, the concentration is usually standardized to a 1% aqueous solution or petroleum-based ointment, applied to the skin for 48 to 72 hours under clinical supervision.
Sodium Molybdate is critical for pediatric patients on TPN, especially neonates and infants who have higher metabolic demands for trace elements.
Because Sodium Molybdate is primarily excreted through the kidneys, patients with chronic kidney disease (CKD) or acute kidney injury (AKI) require careful monitoring. Dose reductions may be necessary to prevent the accumulation of molybdenum, which can lead to hyperuricemia (elevated uric acid levels).
Standard doses are generally well-tolerated in patients with liver disease, as the liver is a primary storage site rather than a primary excretory organ for this mineral. However, in cases of severe biliary obstruction, caution is advised as a small portion of molybdenum is excreted via bile.
Geriatric patients often have a physiological decline in glomerular filtration rate (GFR). Healthcare providers typically start at the lower end of the adult dosing range and monitor renal function closely.
Sodium Molybdate is almost exclusively administered by healthcare professionals in a clinical setting.
In a hospital setting, missed doses are rare as trace elements are part of a scheduled daily infusion. If an oral dose is missed at home, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to catch up.
Signs of acute molybdenum overdose (molybdenosis) are rare but can include:
In the event of a suspected overdose, the infusion should be stopped immediately. Treatment is supportive, focusing on hydration to encourage renal excretion and, in severe cases, the administration of copper to counteract molybdenum-induced copper deficiency.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Regular blood tests are necessary to ensure levels remain within the therapeutic range.
At standard nutritional doses, Sodium Molybdate is generally very well tolerated and side effects are rare. However, when used at the upper limits of intake or in sensitive individuals, the following may occur:
> Warning: Stop taking Sodium Molybdate and call your doctor immediately if you experience any of these.
Prolonged exposure to high levels of Sodium Molybdate can lead to chronic molybdenosis. The primary concern with long-term use is the gradual depletion of copper stores. This can result in:
No FDA black box warnings currently exist for Sodium Molybdate. It is considered safe when used within the established Recommended Dietary Allowances (RDA) and clinical guidelines for parenteral nutrition. However, it must be used with extreme caution in patients with pre-existing hyperuricemia or those with severe renal failure.
Report any unusual symptoms to your healthcare provider. Monitoring of serum molybdenum, copper, and uric acid levels is the standard of care for patients on long-term therapy.
Sodium Molybdate is a potent trace element that must be managed with precision. The most critical safety consideration is the maintenance of the balance between molybdenum and other minerals, particularly copper. Because molybdenum facilitates the excretion of copper, excessive use can lead to a functional copper deficiency, even if dietary copper intake seems adequate. Patients with a history of Wilson’s disease (a condition of copper accumulation) or, conversely, those with Menkes disease (a condition of copper deficiency) must be managed with extreme care when receiving Sodium Molybdate.
No FDA black box warnings for Sodium Molybdate. It is not classified as a high-risk medication in the same category as anticoagulants or opioids, but its potential for metabolic disruption requires professional oversight.
Patients receiving Sodium Molybdate as part of long-term TPN require a comprehensive monitoring plan:
Sodium Molybdate does not typically cause sedation or cognitive impairment. There are no specific restrictions on driving or operating machinery associated with its use, provided the patient is not experiencing acute symptoms of an underlying deficiency or an allergic reaction.
Alcohol consumption can increase uric acid levels and may exacerbate the risk of gout when combined with Sodium Molybdate. Patients are advised to limit alcohol intake, particularly if they have a history of high uric acid or joint pain.
There is no withdrawal syndrome associated with the discontinuation of Sodium Molybdate. However, if a patient on long-term TPN stops receiving molybdenum, they may slowly develop a deficiency over several weeks or months. Tapering is not required, but nutritional status should be monitored by a dietitian or physician.
> Important: Discuss all your medical conditions with your healthcare provider before starting Sodium Molybdate. Ensure your provider is aware of any history of gout, kidney disease, or metal allergies.
There are no absolute drug-drug contraindications where Sodium Molybdate must never be used; however, it should not be mixed in the same syringe or infusion line with medications that are known to precipitate in the presence of trace minerals.
For each major interaction, the mechanism involves competitive inhibition at the enzyme level or antagonistic transport in the renal tubules. The clinical consequence is typically a change in the efficacy of the interacting drug or a mineral imbalance. Management involves regular laboratory monitoring and titration of the trace element dose.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for gout or mineral balance.
Sodium Molybdate must NEVER be used in the following conditions:
Conditions requiring careful risk-benefit analysis include:
There is limited evidence of cross-sensitivity between molybdenum and other transition metals. However, patients who are highly sensitive to nickel or cobalt may occasionally show sensitivity to other metal salts, including Sodium Molybdate. In such cases, patch testing prior to systemic administration may be warranted.
> Important: Your healthcare provider will evaluate your complete medical history, including your mineral status and kidney function, before prescribing Sodium Molybdate.
Sodium Molybdate is classified as an essential trace mineral. During pregnancy, the requirement for molybdenum remains similar to non-pregnant states (RDA of 50 mcg/day).
Molybdenum is naturally excreted in human breast milk.
Sodium Molybdate is FDA-approved for use in pediatric patients as part of parenteral nutrition.
Elderly patients are at a higher risk for Sodium Molybdate accumulation due to the natural age-related decline in kidney function.
Renal impairment is the most significant factor in Sodium Molybdate toxicity.
No specific dose adjustments are required for patients with mild to moderate hepatic impairment. In cases of end-stage liver disease or biliary atresia, clinicians should monitor for potential copper-molybdenum imbalances, as the liver's role in mineral storage may be compromised.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying kidney issues.
Sodium Molybdate ($Na_2MoO_4$) acts as a pro-drug for the essential trace element molybdenum. Once introduced into the body, the molybdate ion is taken up by cells via non-specific anion transporters (such as sulfate transporters). Inside the cell, it enters the molybdenum cofactor (MoCo) biosynthetic pathway. This pathway involves the conversion of GTP into precursor Z, then into molybdopterin, and finally, the insertion of the molybdenum atom to form the active MoCo.
This cofactor is then inserted into the active sites of four major enzymes: Sulfite Oxidase, Xanthine Oxidase, Aldehyde Oxidase, and Mitochondrial Amidoxime Reducing Component (mARC). These enzymes are involved in the transfer of oxygen atoms, a process vital for the detoxification of sulfites and the catabolism of purines and various xenobiotics.
The pharmacodynamic effect of Sodium Molybdate is the restoration or maintenance of these enzymatic activities. In a deficient state, the administration of Sodium Molybdate leads to a rapid decrease in blood sulfite levels and an increase in uric acid production. The onset of action is relatively fast (within hours for enzymatic activation), but the clinical reversal of deficiency symptoms may take several days of consistent administration.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (IV); 40-100% (Oral) |
| Protein Binding | Minimal (primarily as free molybdate or bound to alpha-2-macroglobulin) |
| Half-life | 2-8 hours (plasma); several days (tissue stores) |
| Tmax | Immediate (IV); 1-2 hours (Oral) |
| Metabolism | None (inorganic salt) |
| Excretion | Renal 80-90%; Fecal 10% |
Sodium Molybdate is classified as a Trace Element Supplement. In the USP and EPC systems, it is often grouped under Nutritional Agents. It is related to other trace mineral salts such as Zinc Sulfate, Cupric Sulfate, and Manganese Selenite, which are co-administered in parenteral nutrition to maintain human homeostasis.
Common questions about Sodium Molybdate
Sodium Molybdate is primarily used as a nutritional supplement in patients who are receiving Total Parenteral Nutrition (TPN), which is intravenous feeding. It provides the essential trace element molybdenum, which the body needs to activate enzymes that break down certain amino acids and toxins. Without it, patients on long-term IV nutrition can develop a deficiency characterized by rapid heart rate, headaches, and even coma. Additionally, it is used in specialized medical tests to identify patients with a chemical allergy to molybdenum. It is also found in some medical device contexts, such as standardized allergens for testing reactions to copper-containing intrauterine devices.
When used at the correct nutritional dose, Sodium Molybdate rarely causes side effects. The most common issue observed is an increase in uric acid levels in the blood, which is a natural byproduct of the enzymes that molybdenum activates. In some cases, this can lead to joint pain or symptoms similar to gout if the levels become too high. Some patients may also experience a metallic taste in their mouth or mild nausea if taking an oral form. Because it is usually given as part of a complex IV mixture, it can be difficult to isolate side effects to the molybdenum alone. Always report any new joint swelling or pain to your healthcare provider immediately.
It is generally advised to limit or avoid alcohol while receiving Sodium Molybdate therapy. Alcohol is known to increase the levels of uric acid in the body, and since Sodium Molybdate also increases uric acid production, the combination can significantly raise the risk of developing a painful gout flare or kidney stones. Furthermore, many patients requiring Sodium Molybdate are already in a medically fragile state requiring IV nutrition, and alcohol can complicate their overall nutritional recovery and liver function. You should discuss your alcohol consumption with your doctor to determine what is safe for your specific health situation. If you experience sudden joint pain after drinking alcohol, seek medical advice.
Sodium Molybdate is considered safe and is actually an essential nutrient during pregnancy. The body requires molybdenum to support both maternal metabolism and the developing fetus's neurological system. If a pregnant woman requires Total Parenteral Nutrition, Sodium Molybdate must be included to prevent deficiency in both the mother and the baby. There is no evidence that standard nutritional doses cause birth defects or pregnancy complications. However, like all supplements, it should only be used under strict medical supervision during pregnancy. Your doctor will monitor your mineral levels to ensure the dose is appropriate for both you and your developing child.
The biochemical effects of Sodium Molybdate begin almost immediately after it enters the bloodstream. It quickly binds to the enzymes that require it, such as sulfite oxidase and xanthine oxidase, and starts the process of metabolic detoxification. For patients who are already suffering from a molybdenum deficiency, neurological and physical symptoms may begin to stabilize within 24 to 48 hours of starting the supplement. However, the full restoration of mineral balance in the body's tissues can take several days or even weeks of consistent administration. Your healthcare provider will use blood and urine tests to confirm that the medication is working effectively.
You should not stop taking Sodium Molybdate or any part of your parenteral nutrition without consulting your healthcare provider. While there is no 'withdrawal' effect like you might see with certain blood pressure or anxiety medications, stopping it suddenly can lead to a slow depletion of your molybdenum stores. Over time, this could cause a return of deficiency symptoms, such as metabolic disturbances or neurological issues. If your doctor decides to stop the supplement, they will usually do so because your diet has improved enough to provide the mineral naturally. Always follow the specific plan laid out by your medical team for transitioning off IV nutrition.
If you are receiving Sodium Molybdate in a hospital or clinic setting, the nursing staff will manage the schedule, and missed doses are highly unlikely. If you are using an oral supplement at home and miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed one and continue with your regular routine. Do not take two doses at once to make up for the one you missed, as this could temporarily spike your uric acid levels. If you miss multiple doses, contact your doctor or pharmacist for guidance. Keeping a consistent schedule helps maintain the steady mineral levels your body needs.
There is no clinical evidence to suggest that Sodium Molybdate causes weight gain. It is a trace mineral that does not contain calories and does not directly affect the body's fat storage or appetite. However, because it is often given to patients who are recovering from severe illness or malnutrition via TPN, those patients may see an increase in weight as their overall health improves. This weight gain is typically a positive sign of recovery and is due to the proteins, fats, and carbohydrates in the IV nutrition, not the Sodium Molybdate itself. If you notice sudden or unusual weight gain, it may be due to fluid retention and should be discussed with your doctor.
Sodium Molybdate can interact with other medications, particularly those that affect mineral balance or uric acid. For example, it can interfere with the way your body uses copper, so if you are taking copper supplements, your doctor will need to balance the doses carefully. It may also interact with gout medications like Allopurinol because they both affect the same enzyme system. It is vital to provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. This allows them to adjust your treatment plan to avoid any negative interactions and ensure the Sodium Molybdate is safe for you.
Yes, Sodium Molybdate is available in generic forms, usually as a component of generic multi-trace element injections. Because it is a basic mineral salt, it is not protected by a brand-name patent in its standard injectable form. In the United States, you will most commonly find it as part of a 'Trace Elements Injection' produced by various generic manufacturers. Using the generic version is generally just as effective and safe as any brand-name equivalent, provided it is manufactured according to FDA standards. Your hospital or pharmacy will typically provide the version that is most appropriate for your needs and covered by your insurance.